Clinical trial NCT03611205: Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy
Official title: A Pilot Study to Evaluate the Utility of Interim Digital PET/CT in Predicting Outcomes for Locally Advanced Oropharyngeal Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Oropharyngeal Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Keywords: Oropharyngeal
Squamous Cell Carcinoma
HPV
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2018-08-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This pilot trial studies how well interim digital positron emission tomography (PET)/computed tomography (CT) works in predicting outcomes in participants with oropharyngeal cancer that has spread from its original site of growth to nearby tissues or lymph nodes who are undergoing chemoradiation therapy. Diagnostic procedures, such as PET/CT may help measure a participant's response to treatment.

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the utility of early (i.e. during treatment) digital (d)PET as a diagnostic tool to predict local control 6 months after definitive chemoradiation for patients with locally advanced oropharyngeal carcinoma.

SECONDARY OBJECTIVES:

I. To study the association between dynamic dPET parameters taken at early time points (i.e. during treatment) and complete response (CR) on PET after definitive chemoradiation.

II. To study the association between dynamic dPET parameters taken at early time points (i.e. during) treatment and 2 year LC after definitive chemoradiation.

III. To assess the ability of dynamic dPET compared to conventional PET or conventional-equivalent dPET reconstruction to identify tumor volumes with greater sensitivity at the time of before (dPET1), during (dPET2, dPET3) and after (dPET4, dPET5) chemoradiation.

OUTLINE:

Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.

Eligibility criteria: Inclusion Criteria:

* Patient who will undergo definitive radiation with concurrent chemotherapy with weekly (preferred) or high dose cisplatin for histologically confirmed locally advanced squamous cell carcinoma of the oropharyngeal carcinoma
* Patient must have clinically or radiographically evident measurable disease at the primary site and at nodal station(s). Tonsillectomy or local excision of the primary or nodal disease is not permitted
* P16 and/or human papillomavirus (HPV) status obtained on biopsy specimen
* Low risk classification:

  * HPV positive, T1-3, N1-2b, M0 with =\< 10 pack years smoking history
  * Note: Twenty cigarettes is considered equivalent to one pack.
  * Number of pack years = (number \[No.\] of cigarettes per day x number of years of smoking)/20 OR
  * Intermediate risk classification:

    * HPV positive, T4, N3, M0 and/or HPV positive with \> 10 pack year smoking history
    * HPV negative, T1-3, N1-2b, M0, with =\< 10 pack years smoking history OR
  * High risk classification: HPV negative, T4, N3, M0 and/or HPV negative with \> 10 pack year smoking history
* Patients with no contraindications to PET imaging or cisplatin as stated in the section Exclusion Criteria
* No prior history of radiation therapy
* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Patients with remaining teeth will have undergo a dental evaluation prior to enrollment
* Ability to provide informed consent obtained prior to participation in the study and any related procedures being performed
* Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of the first administration of study treatment. Urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment.

Exclusion Criteria:

* Prior cancers except non-melanoma skin cancer outside of the head and neck unless disease free for 5 years
* Carcinoma of unknown primary, even if p16 positive
* Clinical or radiologic evidence of metastatic disease as defined by disease below the clavicles
* Simultaneous primary cancers or separate bilateral primary tumor sites with the exception of patients with bilateral tonsil cancers
* Subjects who are breast-feeding, or have a positive pregnancy test will be excluded from the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
* Medical contraindications to PET imaging (e.g. pregnancy, nursing mothers, weight greater than 420 pounds)
* Medical contraindications to cisplatin or prior allergic reaction to cisplatin
* Subjects who are unable to receive intravenous contrast due to a contrast allergy or poor renal function
* Subjects who are prisoners
* Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject?s safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigator. This could include severe, active co-morbidities such as:

  * Uncontrolled cardiac disease (hypertension, unstable angina, myocardial infarction within last 6 months, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction)
  * Uncontrolled diabetes
  * Acute bacterial or fungal infection requiring intravenous antibiotics at time of registration
  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration

Primary outcomes:
measure: Quantitative assessments of digital positron emission tomography (dPET) characteristics generated at early time points during treatment
timeFrame: Up to 2 years
Secondary outcomes:
measure: Tumor burden
timeFrame: Up to 2 years
measure: Response rate for each patient local control
timeFrame: At 2 years
measure: Progression-free survival (PFS)
timeFrame: Up to 2 years
measure: Standard uptake volume (SUV) from digital/conventional PET
timeFrame: At 3 months
measure: Metabolic tumor volume (MTV) from digital/conventional PET
timeFrame: At 3 months
measure: Total lesion glycolysis (TLG) from digital/conventional PET
timeFrame: At 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Ohio State University Comprehensive Cancer Center
name: Eric Miller, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: